Key facts
- It has raised $23.5M; the latest was Grant ($2.5M) in Jan 2025.
- Notable investors include National Institutes of Health, Eagle Pharmaceuticals, National Institute on Drug Abuse (NIDA), Thornapple River Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Enalare
- ·The full record, as it builds
Funding rounds
No funding rounds for Enalare are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Enalare
Operator of a biopharmaceutical company intended to provide therapies for patients suffering from acute respiratory conditions. The company's biopharmaceutical platform provides pharmaceutical preparations and medical information for the treatment of opioid addiction, opioid overdose, and opioid dependence, it also comes up with agnostic therapeutic breathing stimulants, enabling patients to get treatment for the life-threatening disease of acute respiratory depression.
- Sector
- Healthcare
- HQ
- Princeton, NJ, United States
- Founded
- 2018
- Employees
- 10
- Website
- enalare.com/
- Ownership
- Privately Held (backing)
Enalare doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Enalare shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Enalare in its N-PORT filings yet. We sweep new filings monthly.